Investigation of hyperuricemia during pegylated-interferon-α2b plus ribavirin combination therapy in patients with chronic hepatitis C

Journal of Digestive Diseases

Volumn 9, Issue 1, 2008, Pages 27-31

  Yamashita, Naoki ^a   Enjoji, Munechika ^a   Kotoh, Kazuhiro ^a   Kato, Masaki ^a   Ueda, Akihiro ^a   Horikawa, Yuki ^a   Tajiri, Hirotaka ^a   Higuchi, Nobito ^a   Kinukawa, Naoko ^b   Nakamuta, Makoto ^c   Takayanagi, Ryoichi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

Author keywords

Chronic hepatitis; Hepatitis C virus; Interferon; Ribavirin; Uric acid

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; URIC ACID;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HEPATITIS C; HUMAN; HYPERURICEMIA; INCIDENCE; MALE; MONOTHERAPY; PATHOGENESIS; PRIORITY JOURNAL; SIDE EFFECT; URIC ACID BLOOD LEVEL; URINARY EXCRETION;

AGED; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; HYPERURICEMIA; INTERFERON ALFA-2B; MALE; MIDDLE AGED; RIBAVIRIN; URIC ACID;

EID: 38849094528     PISSN: 17512972     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1443-9573.2007.00316.x     Document Type: Article

References (32)

1. Davis GL, Esteban-Mur R, Rustgi V et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998; 339: 1493-9.
2. Poynard T, Marcellin P, Lee SS et al. Randomized trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426-32.
3. Becker MA, Roessler BJ. Hyperuricemia and gout. In: Scriver CR, Beaudet AL, Sly WS, eds. The Metabolic and Molecular Basis of Inherited Disease, Vol. 2. New York: McGraw-Hill, 1995; 1655-77.
4. Jossa F, Farinaro E, Panico S et al. Serum uric acid and hypertension: the Olivetti heart study. J Hum Hypertens 1994; 8: 677-81.
5. Sundstrom J, Sullivan L, D'Agostino RB et al. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension 2005; 45: 28-33.
6. Verdecchia P, Schillaci G, Reboldi G et al. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension 2000; 36: 1072-8.
7. Franse LV, Pahor M, Di Bari M et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens 2000; 18: 1149-54.
8. Tykarski A. Evaluation of renal handling of uric acid in essential hypertension: Hyperuricemic related to decreased urate secretion. Nephron 1991; 59: 364-8.
9. Muscelli E, Natali A, Bianchi S et al. Effect of insulin on renal sodium and uric acid handling in essential hypertension. Am J Hypertens 1996; 9: 746-52.
10. Cappuccio FP, Strazzullo P, Farinaro E et al. Uric acid metabolism and tubular sodium handling. Results from a population-based study. JAMA 1993; 270: 354-9.
11. Reaven GM. The kidney: An unwilling accomplice in syndrome X. Am J Kidney Dis 1997; 30: 928-31.
12. DeFronzo R. The effect of insulin on renal sodium metabolism: A review with clinical implications. Diabetologia 1981; 21: 165-71.
13. Rocchini AP. The relationship of sodium sensitivity to insulin resistance. Am J Med Sci 1994; 307 (Suppl. 1): S75-80.
14. Ullman B. IMP dehydrogenase mutants; cell culture model for hyperuricemia. Adv Exp Med Biol 1984; 165: 373-9.
15. Willis RC, Carson DA, Seegmiller JE. Adenosine kinase initiates the major route of ribavirin activation in a cultured human cell line. Proc Natl Acad Sci USA 1978; 75: 3042-4.
16. Puschel GP, Nath A, Jungermann K. Increase of urate formation by stimulation of sympathetic hepatic nerves, circulating noradrenalin and glucagons in the perfused rat liver. FEBS Lett 1987; 219: 145-50.
17. Yamashita S, Matsuzawa Y, Tokunaga K et al. Studies on the impaired metabolism of uric acid in obese subjects; marked reduction of renal urate excretion and its improvement by a low-calorie diet. Int J Obes 1986; 10: 255-64.
18. Hotamisligil GS, Arner P, Caro JF et al. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995; 95: 2409-15.
19. Matsuura F, Yamashita S, Nakamura T et al. Effect of visceral fat accumulation on uric acid metabolism in male obese subjects; visceral fat obesity is linked more closely to overproduction of uric acid than subcutaneous fat obesity. Metabolism 1998; 47: 929-33.
20. Takahashi S, Yamamoto T, Tsutsumi Z et al. Close correlation between visceral fat accumulation and uric acid metabolism in healthy men. Metabolism 1997; 46: 1162-5.
21. Matsubara K, Matsuzawa Y, Jiao S et al. Relationship between hyperglyceridemia and uric acid production in primary gout. Metabolism 1989; 38: 698-701.
22. Leyva F, Wingrove CS, Godsland IF et al. The glycolytic pathway to coronary heart disease; a hypothesis. Metabolism 1998; 47: 657-62.
23. Nishiofuku M, Tsujimoto T, Matsumura Y et al. Intracerebral hemorrhage in a patient receiving combination therapy of pegylated interferon alpha-2b and ribavirin for chronic hepatitis C. Intern Med 2006; 45: 483-4.
24. Feig DI, Kang DH, Nakagawa T et al. Uric acid and hypertension. Curr Hypertens Rep 2006; 8: 111-5.
25. Ward HJ. Uric acid as an independent risk factor in the treatment of hypertension. Lancet 1998; 352: 670-1.
26. Johnson RJ, Kang DH, Feig D et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003; 41: 1183-90.
27. Puig JG, Ruilope LM. Uric acid as a cardiovascular risk factor in arterial hypertension. J Hypertens 1999; 17: 869-72.
28. Asselah T, Rubbia-Brandt L, Marcellin P et.al. Steatosis in chronic hepatitis C: Why does it really matter? Gut 2006; 55: 123-30.
29. Fartoux L, Poujol-Robert A, Guéchot J et al. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005; 54: 1003-8.
30. Muzzi A, Leandro G, Rubbia-Brandt L et al. Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients. J Hepatol 2005; 42: 41-6.
31. Kawaguchi T, Yoshida T, Harada M et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 2004; 165: 1499-508.
32. Houstis N, Rosen ED, Lander ES. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 2006; 440: 944-9.